Hong Kong Declares CBD a Dangerous Drug

Feb.01.2023

CBD is now a controlled substance in Hong Kong, with potential life imprisonment and heavy fines for offenders.

As of February 1st, CBD has been officially classified as a dangerous drug and is now subject to regulation under Hong Kong's Dangerous Drugs Ordinance (Chapter 134).

Following this, the Hong Kong police force and customs department will make every effort to crackdown on drug-related offenses involving CBD.

After the law takes effect, those trafficking and illegally manufacturing CBD and its products can be sentenced to life imprisonment and fined up to HKD 5 million (approximately RMB 4.3 million). Those who possess or use the substance in violation of the Dangerous Drugs Ordinance can be sentenced to seven years in prison and fined up to HKD 1 million (approximately RMB 860,000).

The Hong Kong government previously arranged for a disposal collection of items containing CBD, allowing citizens to voluntarily dispose of them, and assisting those in need with large-scale disposals. As of January 29th, the government has collected approximately 77,400 items containing CBD, mostly skincare products, oral oils, and health supplements.

Reference:

Hong Kong is planning to completely ban the sale of CBD products by the end of 2022.

Starting tomorrow, regulations regarding cannabidiol (CBD) will be enforced and those who violate them will face legal consequences.

Hong Kong plans to ban the sale of CBD products entirely by the end of 2022.

#CBD #Hong Kong #Hong Kong, China #USA

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

EUIPO Rejects Imiracle’s Opposition to ‘Crystal’ Trademark, Citing Lack of Proof of Actual Use in Slovakia

The EUIPO has ruled that Imiracle failed to demonstrate actual commercial use of its “Elfbar Crystal” brand in Slovakia, and therefore rejected in full the company’s opposition to Shenzhen SKE Technology’s application to register the “Crystal” trademark. The EUIPO noted that the sales records submitted by Imiracle were limited in scope and that the product packaging was in Ukrainian, which it found insufficient to prove that the products had been placed on the Slovak market.

Dec.10 by 2FIRSTS.ai

HSSP INTL signs agreement with COTY to expand e-cigarette business in Middle East and Australia

HSSP INTL(03626.HK) partners with COTY to establish e-cigarette venture in UAE, expand distribution of Heaven Gifts brand.

Oct.30 by 2FIRSTS.ai

FDA Rolls Out Online PMTA Platform, a Move That 2Firsts Analysts Say Could Pull Grey-Market Products Toward Formal Compliance

FDA’s launch of a web-based PMTA system signals faster reviews and, 2Firsts experts say, a possible inflection point for the U.S. e-cigarette market’s shift out of the grey zone.

Dec.04

South Korea to Implement Revised Tobacco Control Law from April 24, 2026; Synthetic Nicotine E-cigarettes to be Regulated as Tobacco Products; Stricter Health Warnings and Advertising Restrictions to be Enforced.

South Korea will implement revised Tobacco Business Act in 2026, including e-cigarettes in tobacco definition and stricter regulations.

Dec.29 by 2FIRSTS.ai